NovaBridge Biosciences Announced Sunday, Updated Phase 1b Givastomig Combination Data Showing 79% ORR At 8 Mg/Kg In First-Line HER2-Negative Metastatic Gastroesophageal Adenocarcinoma At ESMO
Share
Why It Matters
NovaBridge shared positive results from early tests of a new cancer medicine. When you see strong medicine test results, it hints the company might be moving forward successfully.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.